Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Heather A. Simmons is active.

Publication


Featured researches published by Heather A. Simmons.


Science | 2009

Caloric restriction delays disease onset and mortality in rhesus monkeys

Rozalyn M. Anderson; Sterling C. Johnson; Erik K. Kastman; Kristopher J. Kosmatka; T. Mark Beasley; David B. Allison; Christina Cruzen; Heather A. Simmons; Joseph W. Kemnitz; Richard Weindruch

Starved to Life? Caloric restriction—reducing the calories ingested by around 30% of that of a normal, fit individual—leads to substantial increases in life span in experimental animals. In an extensive study of caloric restriction in primates, Colman et al. (p. 201) report that rhesus monkeys, which were subjected to caloric restriction as adults and followed for the last 20 years, show decreased mortality and delayed onset of age-related diseases when compared to normally fed control animals. If compliance with such a diet were not so difficult, many humans would be strongly tempted to enjoy the decreased incidence of brain degeneration, cardiovascular disease, diabetes, and cancer apparent in this population of monkeys. Age-associated death and onset of pathologies are delayed by controlled caloric restriction, thus prolonging life span. Caloric restriction (CR), without malnutrition, delays aging and extends life span in diverse species; however, its effect on resistance to illness and mortality in primates has not been clearly established. We report findings of a 20-year longitudinal adult-onset CR study in rhesus monkeys aimed at filling this critical gap in aging research. In a population of rhesus macaques maintained at the Wisconsin National Primate Research Center, moderate CR lowered the incidence of aging-related deaths. At the time point reported, 50% of control fed animals survived as compared with 80% of the CR animals. Furthermore, CR delayed the onset of age-associated pathologies. Specifically, CR reduced the incidence of diabetes, cancer, cardiovascular disease, and brain atrophy. These data demonstrate that CR slows aging in a primate species.


Nature Communications | 2016

A rhesus macaque model of Asian-lineage Zika virus infection

Dawn M. Dudley; Matthew T. Aliota; Emma L. Mohr; Andrea M. Weiler; Gabrielle Lehrer-Brey; Kim L. Weisgrau; Mariel S. Mohns; Meghan E. Breitbach; Mustafa N. Rasheed; Christina M. Newman; Dane D. Gellerup; Louise H. Moncla; Jennifer Post; Nancy Schultz-Darken; Michele L. Schotzko; Jennifer M. Hayes; Josh Eudailey; M. Anthony Moody; Sallie R. Permar; Shelby L. O’Connor; Eva G. Rakasz; Heather A. Simmons; Saverio Capuano; Thaddeus G. Golos; Jorge E. Osorio; Thomas C. Friedrich; David H. O’Connor

Infection with Asian-lineage Zika virus (ZIKV) has been associated with Guillain–Barré syndrome and fetal abnormalities, but the underlying mechanisms remain poorly understood. Animal models of infection are thus urgently needed. Here we show that rhesus macaques are susceptible to infection by an Asian-lineage ZIKV closely related to strains currently circulating in the Americas. Following subcutaneous inoculation, ZIKV RNA is detected in plasma 1 day post infection (d.p.i.) in all animals (N=8, including 2 pregnant animals), and is also present in saliva, urine and cerebrospinal fluid. Non-pregnant and pregnant animals remain viremic for 21 days and for up to at least 57 days, respectively. Neutralizing antibodies are detected by 21 d.p.i. Rechallenge 10 weeks after the initial challenge results in no detectable virus replication, indicating protective immunity against homologous strains. Therefore, Asian-lineage ZIKV infection of rhesus macaques provides a relevant animal model for studying pathogenesis and evaluating potential interventions against human infection, including during pregnancy.


Journal of Neuroinflammation | 2011

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

Christine R. Swanson; Valerie Joers; Viktoriya Bondarenko; Kevin Brunner; Heather A. Simmons; Toni E. Ziegler; Joseph W. Kemnitz; Jeffrey A. Johnson; Marina E. Emborg

BackgroundActivation of the peroxisome proliferator-activated receptor gamma (PPAR-γ) has been proposed as a possible neuroprotective strategy to slow down the progression of early Parkinsons disease (PD). Here we report preclinical data on the use of the PPAR-γ agonist pioglitazone (Actos®; Takeda Pharmaceuticals Ltd.) in a paradigm resembling early PD in nonhuman primates.MethodsRhesus monkeys that were trained to perform a battery of behavioral tests received a single intracarotid arterial injection of 20 ml of saline containing 3 mg of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Twenty-four hours later the monkeys were assessed using a clinical rating scale, matched accordingly to disability, randomly assigned to one of three groups [placebo (n = 5), 2.5 (n = 6) or 5 (n = 5) mg/kg of pioglitazone] and their treatments started. Three months after daily oral dosing, the animals were necropsied.ResultsWe observed significant improvements in clinical rating score (P = 0.02) in the animals treated with 5 mg/kg compared to placebo. Behavioral recovery was associated with preservation of nigrostriatal dopaminergic markers, observed as higher tyrosine hydroxylase (TH) putaminal optical density (P = 0.011), higher stereological cell counts of TH-ir (P = 0.02) and vesicular monoamine transporter-2 (VMAT-2)-ir nigral neurons (P = 0.006). Stereological cell counts of Nissl stained nigral neurons confirmed neuroprotection (P = 0.017). Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0.018). A separate experiment to assess CSF penetration of pioglitazone revealed that 5 mg/kg p.o. induced consistently higher levels than 2.5 mg/kg and 7.5 mg/kg. p.o.ConclusionsOur results indicate that oral administration of pioglitazone is neuroprotective when administered early after inducing a parkinsonian syndrome in rhesus monkeys and supports the concept that PPAR-γ is a viable target against neurodegeneration.


PLOS Pathogens | 2017

Highly efficient maternal-fetal Zika virus transmission in pregnant rhesus macaques

Sydney Nguyen; Kathleen M. Antony; Dawn M. Dudley; Sarah Kohn; Heather A. Simmons; Bryce Wolfe; M. Shahriar Salamat; Leandro B. C. Teixeira; Gregory J. Wiepz; Troy H. Thoong; Matthew T. Aliota; Andrea M. Weiler; Gabrielle L. Barry; Kim L. Weisgrau; Logan J. Vosler; Mariel S. Mohns; Meghan E. Breitbach; Laurel M. Stewart; Mustafa N. Rasheed; Christina M. Newman; Michael E. Graham; Oliver Wieben; Patrick A. Turski; Kevin M. Johnson; Jennifer Post; Jennifer M. Hayes; Nancy Schultz-Darken; Michele L. Schotzko; Josh Eudailey; Sallie R. Permar

Infection with Zika virus (ZIKV) is associated with human congenital fetal anomalies. To model fetal outcomes in nonhuman primates, we administered Asian-lineage ZIKV subcutaneously to four pregnant rhesus macaques. While non-pregnant animals in a previous study contemporary with the current report clear viremia within 10–12 days, maternal viremia was prolonged in 3 of 4 pregnancies. Fetal head growth velocity in the last month of gestation determined by ultrasound assessment of head circumference was decreased in comparison with biparietal diameter and femur length within each fetus, both within normal range. ZIKV RNA was detected in tissues from all four fetuses at term cesarean section. In all pregnancies, neutrophilic infiltration was present at the maternal-fetal interface (decidua, placenta, fetal membranes), in various fetal tissues, and in fetal retina, choroid, and optic nerve (first trimester infection only). Consistent vertical transmission in this primate model may provide a platform to assess risk factors and test therapeutic interventions for interruption of fetal infection. The results may also suggest that maternal-fetal ZIKV transmission in human pregnancy may be more frequent than currently appreciated.


PLOS ONE | 2012

A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys

Sachiko Ohshima-Hosoyama; Heather A. Simmons; Nichole Goecks; Valerie Joers; Christine R. Swanson; Viktoriya Bondarenko; Rebecca Velotta; Kevin Brunner; Laura D. Wood; Ralph H. Hruban; Marina E. Emborg

Glial cell line derived neurotrophic factor (GDNF) is a neurotrophic factor that has neuroprotective effects in animal models of Parkinson’s disease (PD) and has been proposed as a PD therapy. GDNF does not cross the blood brain barrier (BBB), and requires direct intracerebral delivery to be effective. Trojan horse technology, in which GDNF is coupled to a monoclonal antibody (mAb) against the human insulin receptor (HIR), has been proposed to allow GDNF BBB transport (ArmaGen Technologies Inc.). In this study we tested the feasibility of HIRMAb-GDNF to induce neuroprotection in parkinsonian monkeys, as well as its tolerability and safety. Adult rhesus macaques were assessed throughout the study with a clinical rating scale, a computerized fine motor skills task and general health evaluations. Following baseline measurements, the animals received a unilateral intracarotid artery MPTP injection. Seven days later the animals were evaluated, matched according to disability and blindly assigned to receive twice a week iv. treatments (vehicle, 1 or 5 mg/kg HIRmAb-GDNF) for a period of three months. HIRmAb-GDNF did not improve parkinsonian motor symptoms and induced a dose-dependent hypersensitivity reaction. Quantification of dopaminergic striatal optical density and stereological nigral cell counts did not demonstrate differences between treatment groups. Focal pancreatic acinar to ductular metaplasia (ADM) was noted in four of seven animals treated with 1 mg/kg HIRmAb-GDNF; two of four with ADM also had focal pancreatic intraepithelial neoplasia 1B (PanIN-1B) lesions. Minimal to mild, focal to multifocal, nonsuppurative myocarditis was noted in all animals in the 5 mg/kg treatment group. Our results demonstrate that HIRmAb-GDNF dosing in a monkey model of PD is not an effective neuroprotective strategy and may present serious health risks that should be considered when planning future use of the IR antibody as a carrier, or of any systemic treatment of a GDNF-containing molecule.


Journal of Immunology | 2012

Vaccination with Cancer- and HIV Infection-Associated Endogenous Retrotransposable Elements Is Safe and Immunogenic

Jonah B. Sacha; In Jeong Kim; Lianchun Chen; Jakir Hussain Ullah; David Goodwin; Heather A. Simmons; Daniel Schenkman; Frederike Von Pelchrzim; Robert J. Gifford; Francesca A. Nimityongskul; Laura P. Newman; Samantha E. Wildeboer; Patrick B. Lappin; Daisy Hammond; Philip A. Castrovinci; Shari M. Piaskowski; Jason S. Reed; Kerry Beheler; Tharsika Tharmanathan; Ningli Zhang; Sophie Muscat-King; Melanie Rieger; Carla Fernandes; Klaus Rumpel; Joseph P. Gardner; Douglas H. Gebhard; Juliann Janies; Ahmed Shoieb; Brian G. Pierce; Dusko Trajkovic

The expression of endogenous retrotransposable elements, including long interspersed nuclear element 1 (LINE-1 or L1) and human endogenous retrovirus, accompanies neoplastic transformation and infection with viruses such as HIV. The ability to engender immunity safely against such self-antigens would facilitate the development of novel vaccines and immunotherapies. In this article, we address the safety and immunogenicity of vaccination with these elements. We used immunohistochemical analysis and literature precedent to identify potential off-target tissues in humans and establish their translatability in preclinical species to guide safety assessments. Immunization of mice with murine L1 open reading frame 2 induced strong CD8 T cell responses without detectable tissue damage. Similarly, immunization of rhesus macaques with human LINE-1 open reading frame 2 (96% identity with macaque), as well as simian endogenous retrovirus-K Gag and Env, induced polyfunctional T cell responses to all Ags, and Ab responses to simian endogenous retrovirus-K Env. There were no adverse safety or pathological findings related to vaccination. These studies provide the first evidence, to our knowledge, that immune responses can be induced safely against this class of self-antigens and pave the way for investigation of them as HIV- or tumor-associated targets.


Journal of Virology | 2011

Avian-Type Receptor-Binding Ability Can Increase Influenza Virus Pathogenicity in Macaques

Tokiko Watanabe; Kyoko Shinya; Shinji Watanabe; Masaki Imai; Masato Hatta; Chengjun Li; Ben F. Wolter; Gabriele Neumann; Anthony Hanson; Makoto Ozawa; S. Yamada; Hirotaka Imai; Saori Sakabe; Ryo Takano; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Mutsumi Ito; Satoshi Fukuyama; Eiryo Kawakami; Takeo Gorai; Heather A. Simmons; Daniel Schenkman; Kevin Brunner; Saverio Capuano; Jason T. Weinfurter; Wataru Nishio; Yoshimasa Maniwa; Tatsuhiko Igarashi; Akiko Makino; Emily A. Travanty

ABSTRACT The first influenza pandemic of the 21st century was caused by novel H1N1 viruses that emerged in early 2009. An Asp-to-Gly change at position 222 of the receptor-binding protein hemagglutinin (HA) correlates with more-severe infections in humans. The amino acid at position 222 of HA contributes to receptor-binding specificity with Asp (typically found in human influenza viruses) and Gly (typically found in avian and classic H1N1 swine influenza viruses), conferring binding to human- and avian-type receptors, respectively. Here, we asked whether binding to avian-type receptors enhances influenza virus pathogenicity. We tested two 2009 pandemic H1N1 viruses possessing HA-222G (isolated from severe cases) and two viruses that possessed HA-222D. In glycan arrays, viruses possessing HA-222D preferentially bound to human-type receptors, while those encoding HA-222G bound to both avian- and human-type receptors. This difference in receptor binding correlated with efficient infection of viruses possessing HA-222G, compared to those possessing HA-222D, in human lung tissue, including alveolar type II pneumocytes, which express avian-type receptors. In a nonhuman primate model, infection with one of the viruses possessing HA-222G caused lung damage more severe than did infection with a virus encoding HA-222D, although these pathological differences were not observed for the other virus pair with either HA-222G or HA-222D. These data demonstrate that the acquisition of avian-type receptor-binding specificity may result in more-efficient infection of human alveolar type II pneumocytes and thus more-severe lung damage. Collectively, these findings suggest a new mechanism by which influenza viruses may become more pathogenic in mammals, including humans.


Journal of Virology | 2012

Characterization In Vitro and In Vivo of Pandemic (H1N1) 2009 Influenza Viruses Isolated from Patients

Tokiko Watanabe; Masaki Imai; Shinji Watanabe; Kyoko Shinya; Masato Hatta; Chengjun Li; Gabriele Neumann; Makoto Ozawa; Anthony Hanson; Gongxun Zhong; Satoshi Fukuyama; Eiryo Kawakami; Heather A. Simmons; Daniel Schenkman; Kevin Brunner; Saverio Capuano; Jason T. Weinfurter; Anette Kilander; Susanne G. Dudman; M. Suresh; Olav Hungnes; Thomas C. Friedrich; Yoshihiro Kawaoka

ABSTRACT The first influenza pandemic of the 21st century was caused by novel H1N1 viruses that emerged in early 2009. Molecular evolutionary analyses of the 2009 pandemic influenza A H1N1 [A(H1N1)pdm09] virus revealed two major clusters, cluster I and cluster II. Although the pathogenicity of viruses belonging to cluster I, which became extinct by the end of 2009, has been examined in a nonhuman primate model, the pathogenic potential of viruses belonging to cluster II, which has spread more widely in the world, has not been studied in this animal model. Here, we characterized two Norwegian isolates belonging to cluster II, namely, A/Norway/3568/2009 (Norway3568) and A/Norway/3487-2/2009 (Norway3487), which caused distinct clinical symptoms, despite their genetic similarity. We observed more efficient replication in cultured cells and delayed virus clearance from ferret respiratory organs for Norway3487 virus, which was isolated from a severe case, compared with the efficiency of replication and time of clearance of Norway3568 virus, which was isolated from a mild case. Moreover, Norway3487 virus to some extent caused more severe lung damage in nonhuman primates than did Norway3568 virus. Our data suggest that the distinct replicative and pathogenic potentials of these two viruses may result from differences in their biological properties (e.g., the receptor-binding specificity of hemagglutinin and viral polymerase activity).


PLOS ONE | 2014

Cardiac Sympathetic Denervation in 6-OHDA-Treated Nonhuman Primates

Valerie Joers; Kristine Dilley; Shahrose Rahman; Corinne A. Jones; Jeanette Shultz; Heather A. Simmons; Marina E. Emborg

Cardiac sympathetic neurodegeneration and dysautonomia affect patients with sporadic and familial Parkinsons disease (PD) and are currently proposed as prodromal signs of PD. We have recently developed a nonhuman primate model of cardiac dysautonomia by iv 6-hydroxydopamine (6-OHDA). Our in vivo findings included decreased cardiac uptake of a sympathetic radioligand and circulating catecholamines; here we report the postmortem characterization of the model. Ten adult rhesus monkeys (5–17 yrs old) were used in this study. Five animals received 6-OHDA (50 mg/kg iv) and five were age-matched controls. Three months post-neurotoxin the animals were euthanized; hearts and adrenal glands were processed for immunohistochemistry. Quantification of immunoreactivity (ir) of stainings was performed by an investigator blind to the treatment group using NIH ImageJ software (for cardiac bundles and adrenals, area above threshold and optical density) and MBF StereoInvestigator (for cardiac fibers, area fraction fractionator probe). Sympathetic cardiac nerve bundle analysis and fiber area density showed a significant reduction in global cardiac tyrosine hydroxylase-ir (TH; catecholaminergic marker) in 6-OHDA animals compared to controls. Quantification of protein gene protein 9.5 (pan-neuronal marker) positive cardiac fibers showed a significant deficit in 6-OHDA monkeys compared to controls and correlated with TH-ir fiber area. Semi-quantitative evaluation of human leukocyte antigen-ir (inflammatory marker) and nitrotyrosine-ir (oxidative stress marker) did not show significant changes 3 months post-neurotoxin. Cardiac nerve bundle α-synuclein-ir (presynaptic protein) was reduced (trend) in 6-OHDA treated monkeys; insoluble proteinase-K resistant α-synuclein (typical of PD pathology) was not observed. In the adrenal medulla, 6-OHDA monkeys had significantly reduced TH-ir and aminoacid decarboxylase-ir. Our results confirm that systemic 6-OHDA dosing to nonhuman primates induces cardiac sympathetic neurodegeneration and loss of catecholaminergic enzymes in the adrenal medulla, and suggests that this model can be used as a platform to evaluate disease-modifying strategies aiming to induce peripheral neuroprotection.


PLOS ONE | 2018

Ocular and uteroplacental pathology in a macaque pregnancy with congenital Zika virus infection.

Emma L. Mohr; Lindsey N. Block; Christina M. Newman; Laurel M. Stewart; Michelle R. Koenig; Matthew Semler; Meghan E. Breitbach; Leandro B. C. Teixeira; Xiankun Zeng; Andrea M. Weiler; Gabrielle L. Barry; Troy H. Thoong; Gregory J. Wiepz; Dawn M. Dudley; Heather A. Simmons; Andres Mejia; Terry K. Morgan; M. Shahriar Salamat; Sarah Kohn; Kathleen M. Antony; Matthew T. Aliota; Mariel S. Mohns; Jennifer M. Hayes; Nancy Schultz-Darken; Michele L. Schotzko; Eric Peterson; Saverio Capuano; Jorge E. Osorio; Shelby L. O’Connor; Thomas C. Friedrich

Congenital Zika virus (ZIKV) infection impacts fetal development and pregnancy outcomes. We infected a pregnant rhesus macaque with a Puerto Rican ZIKV isolate in the first trimester. The pregnancy was complicated by preterm premature rupture of membranes (PPROM), intraamniotic bacterial infection and fetal demise 49 days post infection (gestational day 95). Significant pathology at the maternal-fetal interface included acute chorioamnionitis, placental infarcts, and leukocytoclastic vasculitis of the myometrial radial arteries. ZIKV RNA was disseminated throughout fetal tissues and maternal immune system tissues at necropsy, as assessed by quantitative RT-PCR for viral RNA. Replicating ZIKV was identified in fetal tissues, maternal uterus, and maternal spleen by fluorescent in situ hybridization for viral replication intermediates. Fetal ocular pathology included a choroidal coloboma, suspected anterior segment dysgenesis, and a dysplastic retina. This is the first report of ocular pathology and prolonged viral replication in both maternal and fetal tissues following congenital ZIKV infection in a rhesus macaque. PPROM followed by fetal demise and severe pathology of the visual system have not been described in macaque congenital ZIKV infection previously. While this case of ZIKV infection during pregnancy was complicated by bacterial infection with PPROM, the role of ZIKV on this outcome cannot be precisely defined, and further nonhuman primate studies will determine if increased risk for PPROM or other adverse pregnancy outcomes are associated with congenital ZIKV infection.

Collaboration


Dive into the Heather A. Simmons's collaboration.

Top Co-Authors

Avatar

Saverio Capuano

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Andres Mejia

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Mariel S. Mohns

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Michele L. Schotzko

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Thomas C. Friedrich

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Andrea M. Weiler

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Dawn M. Dudley

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Meghan E. Breitbach

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Thaddeus G. Golos

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Christina M. Newman

University of Wisconsin-Madison

View shared research outputs
Researchain Logo
Decentralizing Knowledge